| Nov 13 |
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
|
| Oct 3 |
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
|
| Oct 3 |
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
|
| Sep 9 |
Abivax reports 1H results
|
| Sep 9 |
Abivax presents first-half 2024 financial results
|
| Aug 6 |
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
|
| Jul 15 |
Abivax Provides Operational and Key Program Update
|
| Jun 4 |
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
|
